Scientists Unlock How Alzheimer Drug Lecanemab Works

LEUVEN, Belgium — Researchers have discovered exactly how the Alzheimer drug lecanemab works in the brain, revealing that a specific part of the antibody acts as an anchor that reprograms immune cells to clear toxic amyloid plaques. The breakthrough study from Nature, ScienceDaily, News Medical, EurekAlert, PubMed, and Medical Xpress confirms the mechanism behind the first FDA-approved treatment shown to slow cognitive decline in Alzheimer patients. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we curated on this story.

• Lecanemab, marketed as Leqembi, is a monoclonal antibody therapy that clears toxic amyloid plaques and delays cognitive decline in Alzheimer patients.
• Researchers from VIB and KU Leuven demonstrated for the first time that the antibody Fc fragment is essential for engaging microglia, the brain immune cells responsible for clearing plaques.
• The Fc fragment works as an anchor that microglia latch onto when near plaques, reprogramming these cells to clear plaques more efficiently through phagocytosis and lysosomal activity.
• Using an Alzheimer mouse model with human microglial cells, scientists found that antibodies without the Fc fragment had no effect on plaque clearance.
• The study identified SPP1, also known as osteopontin, as a major factor induced by lecanemab treatment that promotes amyloid clearance.
• Single-cell RNA sequencing revealed that lecanemab induces a focused transcriptional program enhancing phagocytosis, lysosomal degradation, metabolic reprogramming, and antigen presentation.
• The findings provide a blueprint for developing next-generation Alzheimer treatments that may activate microglia without requiring antibodies.

Additional Details Reported

The research team created a controlled experimental system using human microglia within an Alzheimer mouse model, allowing them to examine how lecanemab activates human cells and leads to plaque clearance. This approach was cited as a major strength of the study.

Previous studies had suggested that plaque clearance is mediated by activation of microglia, but direct experimental evidence linking microglia activity to lecanemab therapeutic efficacy was lacking. Alternative Fc-independent mechanisms of plaque removal had also been widely proposed.

The study clarifies uncertainties in the field and highlights that effective amyloid removal depends on engagement of microglia through the Fc fragment. This discovery provides critical insights for optimizing anti-amyloid therapies in Alzheimer disease.

Controversies over anti-amyloid immunotherapies had underscored the need to elucidate their mechanisms of action. The new research demonstrates that lecanemab significantly reduces amyloid-beta pathology and associated neuronal damage.

Neither Fc-silenced lecanemab nor microglia deficiency elicited the therapeutic effect despite intact plaque binding, confirming the essential role of the Fc fragment in the treatment mechanism.

How we report: We select the day most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.